Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KRT-232 plus Ruxolitinib in Myelofibrosis with Suboptimal Response
NCT04485260Phase 2Unknown
- Sponsor
- Kartos Therapeutics
- Start
- Jan 2021
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 2 trial of navtemadlin in myelofibrosis (MF), sponsored by Kartos Therapeutics. Status: unknown.
02
Drugs
navtemadlin
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT04485260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04485260.